Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Expanding Into U.S. Tech, Top British PR Firm Freuds Buys Brew Media Relations for $15 Million

A bigger pipeline into new and emerging startups.

Brew PR

Heavy-hitting British communications strategy and public relations firm Freuds has acquired the high-profile boutique agency Brew Media Relations in a stock and cash deal worth $15 million.

The 10-year-old Brew — which was founded by well-known PR exec Brooke Hammerling in her West Village apartment and which is co-helmed by Los Angeles-based CEO Dena Cook — will continue to operate independently, open an office in London and get a seat on Freuds’ board.

(Disclosure: Hammerling is a personal friend to me and my kids, obvious to anyone who looks at her social media feed. That said, this is a big move into the U.S. tech market by an important international PR firm. That said, I am happy for Brooke. That said, it’s still a good tech news story. Enough info? Fine!)

The 20-person Brew has clients that include both big and small tech companies, such as Oracle, uBeam, Daqri, Maker Studios (acquired by Disney), SmartThings (acquired by Samsung) and Refinery29.

In an interview last night, Freuds’ founder, Matthew Freud, said that the deal was good for both firms, giving Brew more resources and bringing a more diverse portfolio of tech companies into Freuds.

“If I was ever going to build a business in America, it would be Brew, so I bought it,” said the ever-quotable Freud. “I paid retail for it and I have never paid retail for anything in my fucking life, ever.”

Please sir, may I have some more?!

Of course! Freud said that he met Hammerling at the tony TED conference years ago via — wait for itBono. “What’s not to love about what this stands for?” he said.

Freud said the $15 million deal will be half stock and half cash, with Hammerling and Cook taking some money off the table.

And although his company works with U.S. Internet firms in Europe, Freud said the purchase would give his firm a “very nice pipeline” of new and emerging startups in the U.S. As to whether that means he will be spending more time with the geeks of Silicon Valley, Freud declared, “I slightly hope not.”


Re/code Decode: The future of Gawker Media and the battle with Hulk Hogan

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh